Cancer Conversations: BTK Inhibitor Therapies for CLL/SLL and MCL in 2022

Cancer Conversations: BTK Inhibitor Therapies for CLL/SLL and MCL in 2022 is organized by Clinical Care Options (CCO), LLC.,Released: November 22, 2022,Expiration: November 21, 2023,Goal:,The goal of this activity is to improve the knowledge, competence, and performance of learners in selecting the optimal BTKi-based regimens for patients with relapsed/refractory CLL/SLL and relapsed/refractory MCL.,Learning Objectives:,Upon completion of this activity, participants should be able to:,• Evaluate emerging BTK inhibitor data considering the potential impact of safety and efficacy results on clinical practice,• Plan BTKi-based therapeutic strategies for patients with R/R CLL/SLL or R/R MCL, taking into consideration global indications and recent practice-changing clinical trial results,• Select and sequence therapy for patients with resistance to or intolerance of first-line BTKi-based therapy to optimize clinical outcomes,• Identify patients who may be eligible for ongoing clinical trials evaluating currently available and emerging BTKis and BTKi-based combinations,Additional details will be posted as soon as information is available.